BIOMAKERS, headquartered in San Francisco, has built an integrated precision oncology ecosystem that combines large-scale molecular diagnostics, longitudinal real-world clinical data, and a deeply annotated tumor biobank. Its AI-native platform links genomic insights directly to patient samples and clinical outcomes, equipping life-science partners with intelligence to de-risk R&D, broaden trial access, and speed decision-making across the drug-development lifecycle. The company operates in more than 20 countries and runs clinical laboratories in Mexico, Brazil, and Argentina, giving it reach into diverse and under-sampled patient populations. BIOMAKERS’ tumor biobank exceeds 100,000 cases, and the firm maintains direct longitudinal connections to patients, physicians, and healthcare institutions. Having spent years assembling this infrastructure, it is now focused on scaling and monetizing the platform by deploying proprietary AI that structures and harmonizes electronic medical record data. This strategy positions BIOMAKERS as foundational infrastructure for global precision oncology R&D.

Total raised

$8M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026